Palmitoylethanolamide for the treatment of centralised chronic pai

Phase 4

• Conditions: Chronic Pain; Anaesthesiology - Pain management

• Registration Number: ACTRN12619000418178
• Lead Sponsor: Daniel Ellyard

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-03-14
• Last Update Posted: 15 July 2019

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

•Chronic pain at least 3 months duration AND
•Evidence of centralised pain/ neuroinflammatory response as evidenced by Symptom Severity Score (from Fibromyalgia Survey Score) greater than or equal to 7/12 AND
•Average pain intensity as measured by modified BPI greater than or equal to 5/10 (moderate or severe) AND
•Pain interference as measure by BPI greater than or equal to 5/10 (moderate or severe)

Exclusion Criteria

•Daily opioids > 120 OME
•Planned procedural intervention within 6 months
•Pre-study use of PEA
•Workers compensation or other ongoing compensation claim
•Major psychiatric disease (BPAD, Psychosis, PTSD)
•Pregnancy or breastfeeding
•Non-English speaking
•Cognitive impairment significant enough to impair informed consent

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Mean pain interference as assessed by the Brief Pain Inventory (BPI)[6 months post baseline]